Theranostic application of 64Cu/177Lu-labeled anti- Trop2 monoclonal antibody in pancreatic cancer tumor models

The human trophoblast cell surface antigen 2 (Trop2 ) is a transmembrane glycoprotein associated with the occurrence, development and poor prognosis of pancreatic cancer. As the conventional techniques show a poor sensitivity and specificity, there is a need for earlier detection and therapy.

This study aims to develop 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody (IMB1636) for PET and SPECT imaging and radioimmunotherapy (RIT)  in pancreatic cancer tumor models. In addition, 18F-FDG PET-CT is used to evaluate the therapy response.

ImmunoPET/SPECT imaging and RIT studies were performed using 64Cu-NOTAIMB1636 and 177Lu-DOTA-IMB1636 in subcutaneous pancreatic cancer tumor models.

The study shows that the Cu64-labelled Ab can diagnose, quantify and monitor Trop2 positive pancreatic tumors and Lu177-labelled Ab can inhibit tumor growth, while the biodistribution of the Lu177 labeled Ab can be followed non-invasively with SPECT, which was confirmed by biodistribution results. In this context imunnoPET imaging can be used as a screening tool for RIT.